Drug Profile
Donepezil - Eisai
Alternative Names: ALLYDONE; Aricept; Aricept D; Aricept Dry Syrup; Aricept Evess; Aricept ODT; Aricept SR; Donepezil hydrochloride; Donepezil SR; E 2020; E 2022; EranzLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Eisai Co Ltd; Pfizer; Teikoku Pharma USA; Teikoku Seiyaku
- Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease; Lewy body disease; Vascular dementia
- Registered Dementia
- Phase III Down syndrome
- No development reported Attention deficit and disruptive behaviour disorders; Migraine
- Discontinued Aphasia; Attention-deficit hyperactivity disorder; Mild cognitive impairment
Most Recent Events
- 23 Dec 2022 Registered for Dementia in Japan (Transdermal)
- 31 Oct 2022 Eisai received Category 2* status for the treatment of dementia with Lewy bodies (DLB) in Japan
- 30 Dec 2021 Teikoku Seiyaku completes a phase-III clinical trials in Alzheimer's disease in Japan, prior to December 2021 (PO) (JapicCTI-194683)